文献速递神经肌肉病

SMN基因剂量对ALS风险与疾病严重程度的影响

The Effect of SMN Gene Dosage on ALS Risk and Disease Severity.
PubMed 文献 · Ann Neurol · 2021-01-15

该研究基于Project MinE全基因组测序数据,纳入6375例ALS患者和2412例对照,评估SMN1和SMN2拷贝数与ALS风险及疾病严重程度的关系。结果显示SMN1和SMN2拷贝数在病例与对照间无统计学差异,且与患者生存期和发病年龄均无关联。

要点

  • SMN1和SMN2拷贝数分布与ALS风险无显著关联。
  • SMN拷贝数与ALS患者生存期及发病年龄均无关联。
  • 生理范围内改变SMN蛋白水平可能不改变ALS病程。

核心结论

  • SMN1或SMN2拷贝数与ALS风险及疾病严重程度均无关联。

研究设计与样本

  • 最大规模多中心病例对照研究,使用Project MinE数据冻结2的全基因组测序数据,纳入6375例ALS患者和2412例对照,并用多重连接依赖探针扩增数据验证拷贝数调用可靠性。

主要发现

  • SMN1和SMN2拷贝数分布在病例与对照间无统计学差异(二项多变量逻辑回归SMN1 p=0.54,SMN2 p=0.49)。
  • SMN拷贝数与患者生存期无关联(Royston-Parmar;SMN1 p=0.78,SMN2 p=0.23)。
  • SMN拷贝数与发病年龄无关联(Royston-Parmar;SMN1 p=0.75,SMN2 p=0.63)。

临床怎么用

  • 针对SMN缺陷的新兴疗法在ALS中改变SMN蛋白水平可能不会改善疾病病程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role of the survival of motor neuron (SMN) gene in amyotrophic lateral sclerosis (ALS) is unclear, with several conflicting reports. A decisive result on this topic is needed, given that treatment options are available now for SMN deficiency. METHODS: In this largest multicenter case control study to evaluate the effect of SMN1 and SMN2 copy numbers in ALS, we used whole genome sequencing data from Project MinE data freeze 2. SMN copy numbers of 6,375 patients with ALS and 2,412 controls were called from whole genome sequencing data, and the reliability of the calls was tested with multiplex ligation-dependent probe amplification data. RESULTS: The copy number distribution of SMN1 and SMN2 between cases and controls did not show any statistical differences (binomial multivariate logistic regression SMN1 p = 0.54 and SMN2 p = 0.49). In addition, the copy number of SMN did not associate with patient survival (Royston-Parmar; SMN1 p = 0.78 and SMN2 p = 0.23) or age at onset (Royston-Parmar; SMN1 p = 0.75 and SMN2 p = 0.63). INTERPRETATION: In our well-powered study, there was no association of SMN1 or SMN2 copy numbers with the risk of ALS or ALS disease severity. This suggests that changing SMN protein levels in the physiological range may not modify ALS disease course. This is an important finding in the light of emerging therapies targeted at SMN deficiencies. ANN NEUROL 2021;89:686-697.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Moisse M, Zwamborn RAJ, van Vugt J, et al. The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. Ann Neurol. 2021. PMID: 33389754. doi:10.1002/ana.26009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。